CAR T-cell therapy for multiple myeloma: state of the art and prospects
Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning
ABSTRACT Introduction Chimeric Antigen Receptor;(CAR) T cells therapies have become
part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
part of the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …
CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions
S Gill, JN Brudno - American Society of Clinical Oncology Educational …, 2021 - ascopubs.org
At the time of writing, five anti-CD19 CAR T-cell products are approved by the US Food and
Drug Administration for seven different indications in lymphoid malignancies, including B …
Drug Administration for seven different indications in lymphoid malignancies, including B …